关注
Julien Kirchgesner
Julien Kirchgesner
Department of Gastroenterology, AP-HP, Hôpital Saint-Antoine, Paris, France
在 aphp.fr 的电子邮件经过验证
标题
引用次数
引用次数
年份
Fungal microbiota dysbiosis in IBD
H Sokol, V Leducq, H Aschard, HP Pham, S Jegou, C Landman, D Cohen, ...
Gut 66 (6), 1039-1048, 2017
12182017
Risk of serious and opportunistic infections associated with treatment of inflammatory bowel diseases
J Kirchgesner, M Lemaitre, F Carrat, M Zureik, F Carbonnel, R Dray-Spira
Gastroenterology 155 (2), 337-346. e10, 2018
5542018
Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease
M Lemaitre, J Kirchgesner, A Rudnichi, F Carrat, M Zureik, F Carbonnel, ...
Jama 318 (17), 1679-1686, 2017
5352017
ECCO guidelines on the prevention, diagnosis, and management of infections in inflammatory bowel disease
T Kucharzik, P Ellul, T Greuter, JF Rahier, B Verstockt, C Abreu, ...
Journal of Crohn's and Colitis 15 (6), 879-913, 2021
2952021
Fecal microbiota transplantation to maintain remission in Crohn’s disease: a pilot randomized controlled study
H Sokol, C Landman, P Seksik, L Berard, M Montil, I Nion-Larmurier, ...
Microbiome 8, 1-14, 2020
2782020
Increased risk of acute arterial events in young patients and severely active IBD: a nationwide French cohort study
J Kirchgesner, L Beaugerie, F Carrat, NN Andersen, T Jess, ...
Gut 67 (7), 1261-1268, 2018
1342018
Predicting, preventing, and managing treatment-related complications in patients with inflammatory bowel diseases
L Beaugerie, JF Rahier, J Kirchgesner
Clinical Gastroenterology and Hepatology 18 (6), 1324-1335. e2, 2020
1212020
The effectiveness of either ustekinumab or vedolizumab in 239 patients with Crohn's disease refractory to anti‐tumour necrosis factor
H Alric, A Amiot, J Kirchgesner, X Tréton, M Allez, Y Bouhnik, L Beaugerie, ...
Alimentary pharmacology & therapeutics 51 (10), 948-957, 2020
1082020
Increased incidence of systemic serious viral infections in patients with inflammatory bowel disease associates with active disease and use of thiopurines
A Wisniewski, J Kirchgesner, P Seksik, C Landman, A Bourrier, ...
United European Gastroenterology Journal 8 (3), 303-313, 2020
1082020
High risk of anal and rectal cancer in patients with anal and/or perianal Crohn’s disease
L Beaugerie, F Carrat, S Nahon, JD Zeitoun, JM Sabaté, L Peyrin-Biroulet, ...
Clinical Gastroenterology and Hepatology 16 (6), 892-899. e2, 2018
1082018
Use of proton pump inhibitors in adults in France: a nationwide drug utilization study
M Lassalle, T Le Tri, M Bardou, M Biour, J Kirchgesner, F Rouby, ...
European journal of clinical pharmacology 76, 449-457, 2020
1052020
Therapeutic management of inflammatory bowel disease in real‐life practice in the current era of anti‐TNF agents: analysis of the French administrative health databases 2009–2014
J Kirchgesner, M Lemaitre, A Rudnichi, A Racine, M Zureik, F Carbonnel, ...
Alimentary pharmacology & therapeutics 45 (1), 37-49, 2017
1052017
Specificities of the intestinal microbiota in patients with inflammatory bowel disease and Clostridium difficile infection
H Sokol, S Jegou, C McQuitty, M Straub, V Leducq, C Landman, ...
Gut microbes 9 (1), 55-60, 2018
1012018
Balancing benefit vs risk of immunosuppressive therapy for individual patients with inflammatory bowel diseases
L Beaugerie, J Kirchgesner
Clinical Gastroenterology and Hepatology 17 (3), 370-379, 2019
982019
ECCO guidelines on inflammatory bowel disease and malignancies
H Gordon, L Biancone, G Fiorino, KH Katsanos, U Kopylov, E Al Sulais, ...
Journal of Crohn's and Colitis 17 (6), 827-854, 2023
852023
Rewiring the altered tryptophan metabolism as a novel therapeutic strategy in inflammatory bowel diseases
C Michaudel, C Danne, A Agus, A Magniez, A Aucouturier, M Spatz, ...
Gut 72 (7), 1296-1307, 2023
802023
Effectiveness and safety of ustekinumab induction therapy for 103 patients with ulcerative colitis: a GETAID multicentre real‐world cohort study
A Amiot, J Filippi, V Abitbol, G Cadiot, D Laharie, M Serrero, R Altwegg, ...
Alimentary Pharmacology & Therapeutics 51 (11), 1039-1046, 2020
682020
Safety of ustekinumab or vedolizumab in pregnant inflammatory bowel disease patients: a multicentre cohort study
P Wils, P Seksik, C Stefanescu, S Nancey, M Allez, ...
Alimentary Pharmacology & Therapeutics 53 (4), 460-470, 2021
672021
Ustekinumab for perianal Crohn's disease: the BioLAP multicenter study from the GETAID
C Chapuis-Biron, J Kirchgesner, B Pariente, Y Bouhnik, A Amiot, ...
Official journal of the American College of Gastroenterology| ACG 115 (11 …, 2020
612020
Risk of acute arterial events associated with treatment of inflammatory bowel diseases: nationwide French cohort study
J Kirchgesner, NN Andersen, F Carrat, T Jess, L Beaugerie
Gut 69 (5), 852-858, 2020
602020
系统目前无法执行此操作,请稍后再试。
文章 1–20